Tumori intestino

Tumori dell'intestino

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

Cancer Chemother Pharmacol. 2010 Oct;66(5):837-44.
Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R.
La combinazione tra sorafenib, inibitore delle chinasi e octreotide LAR è attiva e ben tollerata nei pazienti con carcinoma epatocellulare avanzato (HCC).
Sorafenib-octreotide LAR/carcinoma epatocellulare.

A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendocrine tumor with multiple liver metastases

Endocr J. 2010;57(3):229-36. Epub 2009 Dec 22.
Kondo T, Matsuyama R, Ashihara H, Matsuo Y, Sasaki K, Goto R, Ono K, Takaki Y, Honda Y, Iyama K, Kawashima J, Motoshima H, Tsuruzoe K,Miyamura N, Araki E.
La produzione ectopica di ormone adrenocorticotropo (ACTH) da parte del tumore neuroendocrino pancreatico (p-NET) è relativamente rara, nel tumore metastatico del fegato i recettori della somatostatina, (SSTR-2a) e (SSTR-5), risultano positivi.
Recettori della somatostatina/tumore neuroendocrino pancreatico.

Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor

Langenbecks Arch Surg. 2010 Feb;395(2):185-92.
Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ.
La terapia DOTA-D-Phe [(1)-Tyr (3)-octreotide (DOTATOC)] potrebbe rivelarsi utile per il trattamento di tumori avanzati neuroendocrini pancreatici (NET) con metastasi al fegato.
Octreotide (DOTATOC)/tumori neuroendocrini pancreatici con metastasi al fegato.

Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT

Mol Imaging Biol. 2010 Jan-Feb;12(1):78-84.
Luboldt W, Zöphel K, Wunderlich G, Abramyuk A, Luboldt HJ, Kotzerke J.
Nel cancro della prostata e nelle sue metastasi ossee, i recettori della somatostatina DOTATOC-affini (sottotipi 2 e 5) possono essere visualizzati con Ga-68-DOTATOC PET / CT.
Recettori della somatostatina/cancro della prostata.

Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer

Mol Carcinog. 2012 Aug;51(8):608-18.
León J, Casado J, Carazo A, Sanjuán L, Maté A, Muñoz de Rueda P, de la Cueva P, Quiles R, Ruíz S, Ruíz-Extremera A, Salmerón J.
Melatonin inhibits growth and invasive capacity of colon cancer cells in vitro through its membrane (MT1 and MT2) and/or nuclear receptors (RORα).
MT1- MT2 - RORα

Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma

Tumori. 1992 Dec 31;78(6):383-7.
Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Paolorossi F, Brivio F, Perego M, Tancini G, Conti A, Maestroni G.
Neuroimmunotherapy with low-dose interleukin-2 and MLT(50mg/day orally), does not seem to be effective in terms of tumor regression in metastatic colon cancer patients pretreated with 5-fluorouracil.
Interleukin 2 (IL-2) plus MLT.

Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results

Eur J Cancer. 1993;29A(2):185-9.
Lissoni P, Barni S, Rovelli F, Brivio F, Ardizzoia A, Tancini G, Conti A, Maestroni GJ.
Neuroimmunotherapy with low-dose IL-2 and MLT (50mg/day orally) is a biologically active and well tolerated strategy, capable of determining an apparent control of tumour growth in patients with advanced solid neoplasms.
Interleukin 2 (IL-2) plus .MLT

Pagine

Abbonamento a RSS - Tumori intestino